TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06547554

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xeruborbactam
Description: Experimental

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefiderocol
Description: Experimental

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xeruborbactam/Cefiderocol
Description: A combination of Xeruborbactam and Cefiderocol.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dextrose 5% in water
Description: Placebo
Study: NCT06528288

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector Spinae Plane Block
Description: The erector spinae plane block (ESPB) is a method for injecting local anesthesia to reduce pain related to a surgical procedure. The anesthesia is theorized to spread along the paraspinal fascia and anesthetize a larger area, resulting in patients reporting less pain and using less opioids postoperatively.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Subcutaneous Anesthesia
Description: Subcutaneous anesthesia injection involves placement of local anesthesia under the skin around the surgical incision. This is thought to reduce pain from the incision site postoperatively.
Study: NCT05789745

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human plasma gelsolin
Description: intravenous administration of either 6, 12, 18, or 24 mg/kg at time 0, 12, 36, 60 and 84 hours

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: intravenous administration of saline control at time 0, 12, 36, 60 and 84 hours
Study: NCT04663321

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1942
Description: MK-1942 (5 mg or 10 mg capsules) titrated from 5 mg to 20 mg dose BID or 10 mg BIW over 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1942
Description: MK-1942 (5 mg or 10 mg capsules) titrated from 5 mg to 20 mg dose BID or 10 mg BIW over 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Dose matched placebo capsules BID orally over 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Dose matched placebo capsules BID orally over 4 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dose matched placebo capsules BID orally over 4 weeks.
Study: NCT06088498

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Updating Existing Smartphone App
Description: Participants will be asked to use a recently developed study smartphone application to reduce cravings to smoke for a 5-week period. Through the app, participants will be exposed to smoking extinction trials daily. Participants will be encouraged and reminded to complete 2-5 extinction sessions per day. Each session will present 3-8 cues, and each cue will be presented for 20-40 seconds (average amount of extinction per day will be about 10 minutes). Participants will be encouraged to conduct the extinction sessions when high cravings are expected.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quitline Services
Description: Quitline coaches use cognitive behavioral therapy, reinforcement, and principles of self-efficacy to promote effective behavior change. The quitline approach includes 5 key elements: setting a quit date, coping with triggers, effectively using medications, tobacco proofing, and social support. Individuals who enroll in the quitline's multi-call program receive phone calls and NRT.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quitline Services
Description: Quitline coaches use cognitive behavioral therapy, reinforcement, and principles of self-efficacy to promote effective behavior change. The quitline approach includes 5 key elements: setting a quit date, coping with triggers, effectively using medications, tobacco proofing, and social support. Individuals who enroll in the quitline's multi-call program receive phone calls and NRT.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quitline Services and Smartphone App
Description: In addition to quitline services, participants will download a study app that will allow them to track smoking urges and abstinence. After 48 hours of self-reported abstinence, those in the intervention group will be exposed to smoking extinction trials through the study smartphone app.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quitline Services and Smartphone App
Description: In addition to quitline services, participants will download a study app that will allow them to track smoking urges and abstinence. After 48 hours of self-reported abstinence, those in the intervention group will be exposed to smoking extinction trials through the study smartphone app.
Study: NCT06582758

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pain Psychoeducation
Description: In the pain psychoeducation intervention, participants will be provided a four-minute recording about different pain management strategies (e.g., ice, rest) and accessible resources to promote overall well-being.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pain Psychoeducation
Description: In the pain psychoeducation intervention, participants will be provided a four-minute recording about different pain management strategies (e.g., ice, rest) and accessible resources to promote overall well-being.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful Pain Management
Description: In the mindful pain management intervention, participants will listen to a four minute mindfulness intervention consisting of a 1-minute introduction to mindful pain management and a 3-minute mindfulness practice.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful Pain Management
Description: In the mindful pain management intervention, participants will listen to a four minute mindfulness intervention consisting of a 1-minute introduction to mindful pain management and a 3-minute mindfulness practice.
Study: NCT04829734

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active PBMT-sMF
Description: The Active PBMT-sMF will be applied using MRM® MR5 Prototype manufactured by Multi Radiance Medical (Solon, OH, USA). PBMT-sMF will be applied using the direct contact method with light pressure on the skin. The PBMT-sMF will be applied in four regions of the epicondyle and the application time will be 60 seconds per region. The total dose of PBMT-sMF will be 108,30 J per treatment session.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo PBMT-sMF
Description: The Placebo PBMT-sMF will be applied using MRM® MR5 Prototype manufactured by Multi Radiance Medical (Solon, OH, USA). Placebo PBMT-sMF will be applied using the direct contact method with light pressure on the skin. The Placebo PBMT-sMF will be applied in four regions of the epicondyle and the application time will be 60 seconds per region. The total dose of Placebo PBMT-sMF will be 0 J per treatment session and the sMF will be turned off. The sounds and signals emitted from the device as well as the information displayed on the screen will be identical, regardless of the type of treatment (active or placebo).
Study: NCT06397781

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Skin Cleanser Combination No.1
Description: 1. Mupirocin 2% nasal ointment to the anterior nares to be applied twice daily~2. Chlorhexidine 4% topical soap (Hibiclens) to be used every other day in the shower or bath from the neck down and then completely rinsed.~3. Sulfamethoxazole/trimethoprim (Bactrim): one double strength (DS) tablet (800 mg/160 mg) twice per day for adolescents and adults. Dosing for pediatric patients will be calculated to 5 to 6 mg/kg trimethoprim also given twice daily.
Study: NCT05125159

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: angioplasty guidewire-assisted transseptal puncture or Standard conventional transseptal puncture
Description: Patients randomized to the angioplasty guidewire-assisted transseptal puncture (GW-TSP) group will undergo transseptal puncture with angioplasty guidewire-assistance.~Patients randomized to the conventional transseptal group (Standard Group) will undergo transseptal puncture with BRK needle (St. Jude Medical).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: angioplasty guidewire-assisted transseptal puncture or Standard conventional transseptal puncture
Description: Patients randomized to the angioplasty guidewire-assisted transseptal puncture (GW-TSP) group will undergo transseptal puncture with angioplasty guidewire-assistance.~Patients randomized to the conventional transseptal group (Standard Group) will undergo transseptal puncture with BRK needle (St. Jude Medical).
Study: NCT05894460

Intervention type: DEVICE
Intervention: Chocolate balloon
Description: Vascular preparation with chocolate balloons prior to drug-coated balloon angioplasty

Intervention type: DEVICE
Intervention: Chocolate balloon
Description: Vascular preparation with chocolate balloons prior to drug-coated balloon angioplasty
Study: NCT05994612

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Therapy for Suicide Prevention
Description: 10 sessions of cognitive therapy for suicide prevention plus 9 optional booster sessions

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Services as Usual
Description: Participants will receive services that they would normally receive in the community.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Services as Usual
Description: Participants will receive services that they would normally receive in the community.
Study: NCT06406712

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: retroclavicular block
Description: regional anesthesia

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: retroclavicular block
Description: regional anesthesia
Study: NCT06366607

Intervention type: OTHER
Intervention: high-alert medication administration
Description: high-alert medication administration
Study: NCT05976516

Intervention type: DIAGNOSTIC_TEST
Intervention: CXCL2/CXCL8
Description: Detecte CXCL2/8 content in nucleus pulposus and peripheral blood of patients in each group

Intervention type: DIAGNOSTIC_TEST
Intervention: CXCL2/CXCL8
Description: Detecte CXCL2/8 content in nucleus pulposus and peripheral blood of patients in each group

Intervention type: DIAGNOSTIC_TEST
Intervention: CXCL2/CXCL8
Description: Detecte CXCL2/8 content in nucleus pulposus and peripheral blood of patients in each group

Intervention type: DIAGNOSTIC_TEST
Intervention: CXCL2/CXCL8
Description: Detecte CXCL2/8 content in nucleus pulposus and peripheral blood of patients in each group
Study: NCT05413668

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RVP-001
Description: Intravenous administration of RVP-001

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous administration of saline placebo
Study: NCT01007903

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai Chi exercise
Description: 12-week tai chi exercise class
Study: NCT04826172

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMB-1018972
Description: Modified release (MR) oral tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching oral tablet
Study: NCT06082206

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: thoracic paravertebral block (TPVB)
Description: Bupivacaine 0.25% 20 ml was injected between the costotransverse ligament and the parietal pleura.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PECS group
Description: entering the plane between the pectoralis minor muscle and serratus anterior muscle, and bupivacaine 0.25% 10 ml was deposited in this space
Study: NCT04107662

Intervention type: DEVICE
Intervention: Tbit system
Description: Suspected traumatic brain injury with head CT
Study: NCT04789707

Intervention type: BEHAVIORAL
Intervention: auto-questionnaire
Description: Patients answer the auto questionnaire in last minutes of consultation.

Intervention type: BEHAVIORAL
Intervention: auto-questionnaire
Description: Patients answer the auto questionnaire in last minutes of consultation.
Study: NCT05843435

Intervention type: BEHAVIORAL
Intervention: Go-Nogo-task during functional magnetic resonance imaging
Description: Go-Nogo-task (GNG) implemented as a mixed block- and event-related design paradigm for task-related functional resonance imaging. It is composed of six blocks, each containing an event-related inhibitory control GNG. There are two blocks with an alcohol-related GNG, two blocks with a neutral GNG, and two blocks with a mixed GNG paradigm. The blocks are presented in a counterbalanced fashion between the participants. Each block contains 125 Go-trials and 25 NoGo-trials (ratio 5:1), resulting in 150 trials per block with a block time of 5 minutes. Participants are instructed to press a button whenever a stimulus appears on the screen (Go-trial). The only exception to this rule is when the same stimulus appears twice (NoGo-trial). Stimulus material consists of 60 alcohol-related and 60 neutral pictures, presented in a pseudo-randomized order.

Intervention type: BEHAVIORAL
Intervention: Go-Nogo-task during functional magnetic resonance imaging
Description: Go-Nogo-task (GNG) implemented as a mixed block- and event-related design paradigm for task-related functional resonance imaging. It is composed of six blocks, each containing an event-related inhibitory control GNG. There are two blocks with an alcohol-related GNG, two blocks with a neutral GNG, and two blocks with a mixed GNG paradigm. The blocks are presented in a counterbalanced fashion between the participants. Each block contains 125 Go-trials and 25 NoGo-trials (ratio 5:1), resulting in 150 trials per block with a block time of 5 minutes. Participants are instructed to press a button whenever a stimulus appears on the screen (Go-trial). The only exception to this rule is when the same stimulus appears twice (NoGo-trial). Stimulus material consists of 60 alcohol-related and 60 neutral pictures, presented in a pseudo-randomized order.

Intervention type: OTHER
Intervention: Resting-state functional magnetic resonance imaging
Description: An fMRI (multiband-echo-planar imaging) blood oxygenated level dependent (BOLD) protocol is run during 6 minutes of rest. This protocol allows the assessment of connectivity measures at rest, which can be compared to connectivity changes during the GNG task.

Intervention type: OTHER
Intervention: Resting-state functional magnetic resonance imaging
Description: An fMRI (multiband-echo-planar imaging) blood oxygenated level dependent (BOLD) protocol is run during 6 minutes of rest. This protocol allows the assessment of connectivity measures at rest, which can be compared to connectivity changes during the GNG task.
Study: NCT05399069

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VGR-R01
Description: Gene Replacement Therapy
Study: NCT06513494

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active Students Education plus Teacher Training
Description: The teacher undergoes 30 hours of self-instructional training on vaccination through an online platform tailored for the relevant age group. Additionally, students receive active vaccinations and health education over two months

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active Students Education
Description: Students receive active vaccinations and health education over two months.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Basic Health Unit Active Orientation
Description: Nurses from basic health units will conduct an active orientation session at schools about vaccination for students.

Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Description: No project interventions will be carried out.
Study: NCT05962866

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: I and II. Performing Leopold Maneuvers by the pregnant
Description: 24-32 and 32-38 days of pregnancy by the pregnant woman. 1st and 2nd leoppold maneuvers are performed by the pregnant woman, 2 times between weeks.
Study: NCT05822557

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bolus Pouch Feed
Description: Following the 7-day baseline period, all patients will enter the 28-day intervention period, where they will receive the intervention feed daily. The feed prescription will be determined on an individual basis by the Dietitian responsible for the patient's nutritional management
Study: NCT06243198

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lebrikizumab
Description: Administered subcutaneously (SC)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered subcutaneously (SC)
Study: NCT05794425

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine A
Description: 3-5 mg per kilogram per day.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Umbilical cord blood & Umbilical cord derived mesenchymal stem cells
Description: Intravenous infusion of umbilical cord blood and umbilical cord derived mesenchymal stem cells (5-8×10\^7) at 1 week interval.
Study: NCT05842317

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib Plus Tislelizumab
Description: Lenvatinib is 12mg/d for body weight \>= 60kg, 8mg/d for body weight \<60kg, once daily orally, once a day, after meals (take at the same time every day as much as possible); Tislelizumab is administered intravenously at a dose of 200mg/q3w.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib Plus Tislelizumab
Description: Lenvatinib is 12mg/d for body weight \>= 60kg, 8mg/d for body weight \<60kg, once daily orally, once a day, after meals (take at the same time every day as much as possible); Tislelizumab is administered intravenously at a dose of 200mg/q3w.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transarterial Chemoembolization(TACE)
Description: A catheter is inserted through a small incision in the groin and guided to the hepatic artery, which supplies blood to the liver;A contrast dye is injected through the catheter to help visualize the blood vessels in the liver; A mixture of chemotherapy drugs and an embolic agent (such as small beads or gel foam) is injected through the catheter and into the artery that feeds the tumor;The embolic agent helps to block the blood flow to the tumor, which starves it of oxygen and nutrients; The chemotherapy drugs are then trapped in the tumor.
Study: NCT06452537

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab will be intravenously administered as the dosage of 8 mg/kg every 4 weeks, with oral prednisone.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone tapering protocol : If the starting dose is over 20mg/day, then reduce by one tablet weekly. Until the dose is reduced to 20mg/day then 20mg/day for two weeks→17.5mg/day for two weeks→12.5mg for four weeks→10mg for four weeks→7.5mg as a maintain dosage

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone tapering protocol : If the starting dose is over 20mg/day, then reduce by one tablet weekly. Until the dose is reduced to 20mg/day then 20mg/day for two weeks→17.5mg/day for two weeks→12.5mg for four weeks→10mg for four weeks→7.5mg as a maintain dosage
Study: NCT03920111

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: IMOJEV
Description: live attenuated Japanese encephalitis (JE) vaccine IMOJEV®

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: IMOJEV
Description: live attenuated Japanese encephalitis (JE) vaccine IMOJEV®

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: IMOJEV
Description: live attenuated Japanese encephalitis (JE) vaccine IMOJEV®
Study: NCT05873049

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MolecuLight
Description: MolecuLight is a handheld fluorescence imaging device that is utilized to help real-time visualize clinically undetectable fluorescent bacteria in wounds. It emits a 405 nm wavelength of safe violet light, which interacts with the wound tissue and bacteria causing certain bacteria to emit red or cyan fluorescence. The fluorescence signals were then captured by MolecuLight and those with bacteria at levels of ≥ 10\^4 colony forming units per gram (CFU/g) will be detected and displayed on the screen.
Study: NCT04892641

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epetraborole
Description: Epetraborole hydrochloride 250 mg tablets for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epetraborole
Description: Epetraborole hydrochloride 250 mg tablets for oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo for 250 mg epetraborole hydrochloride tablets for oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo for 250 mg epetraborole hydrochloride tablets for oral administration
Study: NCT05980806

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor 60 mg
Description: Participants will receive selinexor 60 mg oral tablets QW.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor 60 mg
Description: Participants will receive selinexor 60 mg oral tablets QW.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor 40 mg
Description: Participants will receive selinexor 40 mg oral tablets QW.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor 40 mg
Description: Participants will receive selinexor 40 mg oral tablets QW.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Participants will receive ruxolitinib 5 mg or 10 mg twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Participants will receive ruxolitinib 5 mg or 10 mg twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Participants will receive ruxolitinib 5 mg or 10 mg twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Participants will receive ruxolitinib 5 mg or 10 mg twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pacritinib
Description: Participants will receive pacritinib 200 mg twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pacritinib
Description: Participants will receive pacritinib 200 mg twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pacritinib
Description: Participants will receive pacritinib 200 mg twice daily.
Study: NCT05522621

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TJAOA102
Description: Once enrolled, participants will be administrated TJAOA102
Study: NCT03971630

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemedicine
Description: Patients will be followed up using the MyVENT System and APP